Answers are grounded in this paper and cite their sources.
Case report demonstrates tumor regression following 177Lu-FAP-2286 and reduced-dose chemotherapy in metastatic extraskeletal Ewing sarcoma, highlighting radioligand therapy potential.
A 23-year-old man with metastatic extraskeletal Ewing sarcoma, who was unable to tolerate standard-dose chemotherapy, received 1 cycle of 177Lu-FAP-2286, followed by 2 cycles of reduced-dose ifosfamide/epirubicin/mesna chemotherapy. Follow-up 68Ga-FAP-2286 PET/CT at 2 months showed a marked metabolic response with reduced tumor size and tracer uptake. No adverse events were observed. The patient remained symptom-free at 2 months. This case suggests that 177Lu-FAP-2286 combined with chemotherapy may have clinical utility in advanced Ewing sarcoma.
No takes yet. Share an insight, caveat, or question.
Mou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: